<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Daily aspirin reduces the long-term incidence of some <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, but effects on mortality due to some <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> appear after only a few years, suggesting that it might also reduce growth or <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We established the frequency of distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> in patients who developed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> during trials of daily aspirin versus control </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Our analysis included <z:hpo ids='HP_0000001'>all</z:hpo> five large randomised trials of daily aspirin (≥75 mg daily) versus control for the prevention of vascular events in the UK </plain></SENT>
<SENT sid="3" pm="."><plain>Electronic and paper records were reviewed for <z:hpo ids='HP_0000001'>all</z:hpo> patients with incident <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The effect of aspirin on risk of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> at presentation or on subsequent follow-up (including post-trial follow-up of in-trial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>) was stratified by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> histology (<z:mp ids='MP_0009308'>adenocarcinoma</z:mp> vs other) and clinical characteristics </plain></SENT>
<SENT sid="5" pm="."><plain>FINDINGS: Of 17,285 trial participants, 987 had a new solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosed during mean in-trial follow-up of 6·5 years (SD 2·0) </plain></SENT>
<SENT sid="6" pm="."><plain>Allocation to aspirin reduced risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> with distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (<z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, hazard ratio [HR] 0·64, 95% CI 0·48-0·84, p=0·001; <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, HR 0·54, 95% CI 0·38-0·77, p=0·0007; other solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, HR 0·82, 95% CI 0·53-1·28, p=0·39), due mainly to a reduction in proportion of <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> that had metastatic versus <z:e sem="disease" ids="C0277565" disease_type="Disease or Syndrome" abbrv="">local disease</z:e> (odds ratio 0·52, 95% CI 0·35-0·75, p=0·0006) </plain></SENT>
<SENT sid="7" pm="."><plain>Aspirin reduced risk of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> at initial diagnosis (HR 0·69, 95% CI 0·50-0·95, p=0·02) and risk of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> on subsequent follow-up in patients without <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> initially (HR 0·45, 95% CI 0·28-0·72, p=0·0009), particularly in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (HR 0·26, 95% CI 0·11-0·57, p=0·0008) and in patients who remained on trial treatment up to or after diagnosis (HR 0·31, 95% CI 0·15-0·62, p=0·0009) </plain></SENT>
<SENT sid="8" pm="."><plain>Allocation to aspirin reduced <z:hpo ids='HP_0011420'>death</z:hpo> due to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in patients who developed <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, particularly in those without <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> at diagnosis (HR 0·50, 95% CI 0·34-0·74, p=0·0006) </plain></SENT>
<SENT sid="9" pm="."><plain>Consequently, aspirin reduced the overall risk of fatal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> in the trial populations (HR 0·65, 95% CI 0·53-0·82, p=0·0002), but not the risk of other fatal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (HR 1·06, 95% CI 0·84-1·32, p=0·64; difference, p=0·003) </plain></SENT>
<SENT sid="10" pm="."><plain>Effects were independent of age and sex, but absolute benefit was greatest in smokers </plain></SENT>
<SENT sid="11" pm="."><plain>A low-dose, slow-release formulation of aspirin designed to inhibit platelets but to have little systemic bioavailability was as effective as higher doses </plain></SENT>
<SENT sid="12" pm="."><plain>INTERPRETATION: That aspirin prevents distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> could account for the early reduction in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>deaths</z:hpo> in trials of daily aspirin versus control </plain></SENT>
<SENT sid="13" pm="."><plain>This finding suggests that aspirin might help in treatment of some <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and provides proof of principle for pharmacological intervention specifically to prevent distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>FUNDING: None </plain></SENT>
</text></document>